<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2502">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05128591</url>
  </required_header>
  <id_info>
    <org_study_id>AD-109BE</org_study_id>
    <nct_id>NCT05128591</nct_id>
  </id_info>
  <brief_title>A Study to Compare Pharmacokinetic Parameters and Safety Profiles Between AD-109 and AD-1091</brief_title>
  <official_title>An Open-label, Randomized, Single-dose, 2-sequence, 2-period, Crossover, Phase 1 Study Under Fed State to Evaluate the Safety and Pharmacokinetics of AD-109 in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Addpharma Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Addpharma Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-109&#xD;
      in healthy male subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the pharmacokinetic characteristics and safety&#xD;
      profiles of AD-109 compared with AD-1091 in healthy male subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 9, 2021</start_date>
  <completion_date type="Anticipated">December 26, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 20, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Plasma Concentration (Cmax)</measure>
    <time_frame>pre-dose to 34 hours</time_frame>
    <description>Cmax of Rivaroxaban</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve in time plot (AUCt)</measure>
    <time_frame>pre-dose to 34 hours</time_frame>
    <description>AUCt of Rivaroxaban</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Embolism and Thrombosis</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Administration of AD-1091, 1tab., QD, Per oral / Period 2: Administration of AD-109, 1tab., QD, Per oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Administration of AD-109, 1tab., QD, Per oral / Period 2: Administration of AD-1091, 1tab., QD, Per oral</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban 18mg Oral Tablet</intervention_name>
    <description>AD-109 (Rivaroxaban 18mg) Oral Tablet</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban 20 MG Oral Tablet</intervention_name>
    <description>AD-1091 (Rivaroxaban 20mg) Oral Tablet</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body weight equal to or greater than 50kg and Body mass index (BMI) between 18.0 kg/m2&#xD;
             and 30.0 kg/m2 at the time of screening visit&#xD;
&#xD;
          -  The Age equal to or greater than 19 in healthy male volunteers at the time of&#xD;
             screening visit&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with Medical history increasing the risk of bleeding&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Si-Beum Lee, Ph.D</last_name>
    <phone>+82-31-5696</phone>
    <email>sblee@addpharma.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>H+ Yangji Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 10, 2021</study_first_submitted>
  <study_first_submitted_qc>November 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2021</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Embolism and Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

